Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

7.155 -0.175 (-2.39%)
Streaming Delayed Price Updated: 11:24 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Breakout Momentum Plays You Need to Know About
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
4 Biotech Stocks Lifting Off As Momentum Builds
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. 
Via Benzinga
In today's session, these stocks are experiencing unusual volume.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
Gold Falls 1%; SLB Posts Better-Than-Expected Q3 Earnings
 
Via Benzinga
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder
Via Stocktwits
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Earnings Preview: Omeros
 
Via Benzinga
Examining the Future: Omeros's Earnings Outlook
 
Via Benzinga
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
Satellogic, Hewlett Packard Enterprise, Bitfarms And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Why J.B. Hunt Transport Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Find out if the deal Omeros announced is enough of a reason to buy this stock. 
Via The Motley Fool
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside
The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart. 
Via Stocktwits
Hims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31. 
Via Benzinga
Topics Stocks
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion and tiered royalties. 
Via Benzinga
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
 
Via Benzinga
Omeros Rockets Skyward on $2.1 Billion Novo Nordisk Deal, Reshaping Biotech Landscape
In a dramatic turn of events that sent shockwaves through the biotechnology sector, Omeros Corporation (NASDAQ: OMER) witnessed its stock catapult by an astounding nearly 150% after announcing a... 
Via MarketMinute
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk
Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases. 
Via Investor's Business Daily
Here are the top movers in Wednesday's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
Gapping stocks in Wednesday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
S&P 500 Gains 1%; Bank of America Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Omeros Posts 2,652 Percent Sales Jump
Via The Motley Fool
Omeros Corp (NASDAQ:OMER) Reports Q2 2025: Narrowed Losses, Regulatory Progress, and Market Optimism
Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism. 
Via Chartmill
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost
The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 
Via Stocktwits
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision
H.C. Wainwright's Brandon Folkes initiated Omeros with a Buy. 
Via Benzinga
This Domino's Pizza Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For May 15, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.